{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:37:47Z","timestamp":1778924267855,"version":"3.51.4"},"reference-count":97,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Metabolische unterw\u00fcnschte Arzneimittelwirkungen (mUAW) von Psychopharmaka haben\n                    erhebliche gesundheitsbezogene und \u00f6konomische Relevanz. Zu den mUAW geh\u00f6ren\n                    Gewichtszunahme, gest\u00f6rte Glukosetoleranz, Diabetes mellitus und Dyslipid\u00e4mie.\n                    Fast alle Antipsychotika (AP) und viele Antidepressiva (AD) sowie\n                    Stimmungsstabilisatoren k\u00f6nnen zu mUAW, insbesondere Gewichtszunahme f\u00fchren. Die\n                    Gewichtsentwicklung in den ersten Wochen bis Monaten nach Initialisierung einer\n                    Therapie ist der st\u00e4rkste Pr\u00e4diktor f\u00fcr Gewichtszunahme assoziiert mit AP und\n                    AD. Die wichtigsten Risikofaktoren f\u00fcr mUAW sind antagonistische Effekte an\n                        H1-, 5-HT2C- und M3-Rezeptoren sowie\n                    antidopaminerge Effekte, wobei die Beeinflussung zahlreicher weiterer Systeme\n                    relevant ist. Ein systematisches Monitoring metabolischer Parameter sollte bei\n                    Therapie mit allen Substanzen durchgef\u00fchrt werden, die mit einem erh\u00f6hten Risiko\n                    f\u00fcr mUAW assoziiert sind. Lebensstilver\u00e4ndernde und di\u00e4tetische Ma\u00dfnahmen,\n                    Bewegungstherapie, Dosisreduktion, Umstellung und Beendigung der Medikation\n                    sowie eine zus\u00e4tzliche Therapie mit Metformin und Topiramat sind evidenzbasierte\n                    Therapieoptionen bei AP-assoziierter Gewichtszunahme, wobei auch die\n                    GLP-1-Rezeptoragonisten wie Liraglutid vielversprechend sind.<\/jats:p>","DOI":"10.1055\/a-2405-5087","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T23:13:56Z","timestamp":1727133236000},"page":"95-103","source":"Crossref","is-referenced-by-count":1,"title":["Metabolische unerw\u00fcnschte Arzneimittelwirkungen von\n                    Psychopharmaka"],"prefix":"10.1055","volume":"93","author":[{"given":"Maximilian","family":"Gahr","sequence":"additional","affiliation":[{"name":"Krankenhaus f\u00fcr Psychiatrie, Psychotherapie und Psychosomatische\n                    Medizin, Schloss Werneck, Werneck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute\n                    treatment of adults with major depressive disorder: a systematic review and\n                    network meta-analysis","volume":"391","author":"A Cipriani","year":"2018","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute\n                    treatment of adults with multi-episode schizophrenia: a systematic review and\n                    network meta-analysis","volume":"394","author":"M Huhn","year":"2019","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","article-title":"Psychotropic Drug-Related Weight Gain and Its Treatment","volume":"181","author":"R S McIntyre","year":"2024","journal-title":"Am J Psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euroneuro.2022.10.001","article-title":"Excess resource use and costs of physical comorbidities in individuals with\n                    mental health disorders: A systematic literature review and meta-analysis","volume":"66","author":"J Simon","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/gps.2409","article-title":"Diabetes incidence associated with depression and antidepressants in the\n                    Melbourne Longitudinal Studies on Healthy Ageing (MELSHA)","volume":"25","author":"E Atlantis","year":"2010","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-017-0052-1","article-title":"The association of depression and diabetes across methods, measures, and study\n                    contexts","volume":"4","author":"J C Hunter","year":"2018","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jpsychores.2013.09.008","article-title":"Depression, anxiety, and prevalent diabetes in the Chinese population: findings\n                    from the China Kadoorie Biobank of 0.5 million people","volume":"75","author":"B Mezuk","year":"2013","journal-title":"J Psychosom Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jad.2024.03.003","article-title":"Association between depression and diabetes mellitus and the impact of their\n                    comorbidity on mortality: Evidence from a nationally representative study","volume":"354","author":"J Cai","year":"2024","journal-title":"J Affect Disord"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archgenpsychiatry.2009.50","article-title":"Major depressive disorder and hypothalamic-pituitary-adrenal axis activity:\n                    results from a large cohort study","volume":"66","author":"S A Vreeburg","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.13217","article-title":"Cortisol dysregulation: the bidirectional link between stress, depression, and\n                    type 2 diabetes mellitus","volume":"1391","author":"J J Joseph","year":"2017","journal-title":"Ann N Y Acad Sci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jpsychires.2023.05.016","article-title":"Prevalence and clinical correlates of abnormal lipid metabolism in first-episode\n                    and drug-naive patients with major depressive disorder: A large-scale\n                    cross-sectional study","volume":"163","author":"J Hu","year":"2023","journal-title":"J Psychiatr Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S2215-0366(16)30262-0","article-title":"The association between first-episode psychosis and abnormal glycaemic control:\n                    systematic review and meta-analysis","volume":"3","author":"B I Perry","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.schres.2016.09.026","article-title":"Meta-analysis of glucose tolerance, insulin, and insulin resistance in\n                    antipsychotic-naive patients with nonaffective psychosis","volume":"179","author":"A M Greenhalgh","year":"2017","journal-title":"Schizophr Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2017.03.031","article-title":"Lipid profile disturbances in antipsychotic-naive patients with first-episode\n                    non-affective psychosis: A systematic review and meta-analysis","volume":"190","author":"B Misiak","year":"2017","journal-title":"Schizophr Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2015.05.004","article-title":"Metabolic syndrome in drug-naive and drug-free patients with schizophrenia and\n                    in their siblings","volume":"166","author":"A Enez Darcin","year":"2015","journal-title":"Schizophr Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2147\/PPA.S110632","article-title":"Long-term antidepressant use: patient perspectives of benefits and adverse\n                    effects","volume":"10","author":"C Cartwright","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1055\/s-0037-1616420","article-title":"Metabolische Nebenwirkungen von Psychopharmaka: Eine Analyse von Daten aus\n                    Fachinformationen","volume":"35","author":"M Gahr","year":"2016","journal-title":"Nervenheilkunde"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.5498\/wjp.v11.i10.696","article-title":"Metabolic disturbances associated with antipsychotic drug treatment in patients\n                    with schizophrenia: State-of-the-art and future perspectives","volume":"11","author":"S C Chang","year":"2021","journal-title":"World J Psychiatry"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with\n                    schizophrenia, predictors of metabolic dysregulation, and association with\n                    psychopathology: a systematic review and network meta-analysis","volume":"7","author":"T Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in\n                    schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"S Leucht","year":"2013","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia:\n                    a meta-analysis","volume":"373","author":"S Leucht","year":"2009","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/wps.21036","article-title":"Metabolic side effects in persons with schizophrenia during mid- to long-term\n                    treatment with antipsychotics: a network meta-analysis of randomized controlled\n                    trials","volume":"22","author":"A Burschinski","year":"2023","journal-title":"World Psychiatry"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/jamapsychiatry.2014.414","article-title":"An electronic health records study of long-term weight gain following\n                    antidepressant use","volume":"71","author":"S R Blumenthal","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","article-title":"Antidepressants and body weight: a comprehensive review and meta-analysis","volume":"71","author":"A Serretti","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/oby.22969","article-title":"Antidepressant Medications and Weight Change: A Narrative Review","volume":"28","author":"H Gill","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"ref27","first-page":"1505","article-title":"Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review","volume":"13","author":"L Sepulveda-Lizcano","year":"2023","journal-title":"Eur J Investig Health Psychol Educ"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2147\/IJGM.S36444","article-title":"Effect of milnacipran on body weight in patients with fibromyalgia","volume":"5","author":"L M Arnold","year":"2012","journal-title":"Int J Gen Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/NDT.S33679","article-title":"Diabetes mellitus and comorbid depression: improvement of both diseases with\n                    milnacipran. A replication study (results of the Austrian Major Depression\n                    Diabetes Mellitus study group)","volume":"8","author":"H Abrahamian","year":"2012","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/JCP.0000000000001481","article-title":"A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or\n                    Risperidone in Overweight Individuals With Schizophrenia","volume":"41","author":"S Weizman","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.genhosppsych.2022.07.006","article-title":"A systematic review of licensed weight-loss medications in treating\n                    antipsychotic-induced weight gain and obesity in schizophrenia and\n                    psychosis","volume":"78","author":"K Lee","year":"2022","journal-title":"Gen Hosp Psychiatry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40345-023-00313-8","article-title":"Controversies regarding lithium-associated weight gain: case-control study of\n                    real-world drug safety data","volume":"11","author":"W Greil","year":"2023","journal-title":"Int J Bipolar Disord"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2165\/00002018-200124130-00004","article-title":"Bodyweight gain and anticonvulsants: a comparative review","volume":"24","author":"P Jallon","year":"2001","journal-title":"Drug Saf"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40345-016-0068-y","article-title":"Lithium side effects and toxicity: prevalence and management strategies","volume":"4","author":"M Gitlin","year":"2016","journal-title":"Int J Bipolar Disord"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00228-018-2517-2","article-title":"Weight changes associated with antiepileptic mood stabilizers in the treatment\n                    of bipolar disorder","volume":"74","author":"K P Grootens","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1399-5618.2006.00308.x","article-title":"Effects of lamotrigine and lithium on body weight during maintenance treatment\n                    of bipolar I disorder","volume":"8","author":"G Sachs","year":"2006","journal-title":"Bipolar Disord"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40263-014-0192-0","article-title":"Pregabalin: a review of its use in adults with generalized anxiety disorder","volume":"28","author":"J E Frampton","year":"2014","journal-title":"CNS Drugs"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jpsychires.2004.02.002","article-title":"Early prediction of changes in weight during six weeks of treatment with\n                    antidepressants","volume":"38","author":"H Himmerich","year":"2004","journal-title":"J Psychiatr Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1192\/j.eurpsy.2023.2417","article-title":"Predicting antipsychotic-induced weight gain in first episode psychosis \u2013 A\n                    field-wide systematic review and meta-analysis of non-genetic prognostic\n                    factors","volume":"66","author":"I Fitzgerald","year":"2023","journal-title":"Eur Psychiatry"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e1417","DOI":"10.4088\/JCP.14m09358","article-title":"Importance of early weight changes to predict long-term weight gain during\n                    psychotropic drug treatment","volume":"76","author":"F Vandenberghe","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jpsychires.2018.10.021","article-title":"Early weight gain predicts later metabolic syndrome in depressed patients\n                    treated with antidepressants: Findings from the METADAP cohort","volume":"107","author":"K El Asmar","year":"2018","journal-title":"J Psychiatr Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e802","DOI":"10.4088\/JCP.14m09212","article-title":"Clinical risk factors for weight gain during psychopharmacologic treatment of\n                    depression: results from 2 large German observational studies","volume":"76","author":"S Kloiber","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic\n                    categorization of the long-term weight course","volume":"43","author":"S Gebhardt","year":"2009","journal-title":"J Psychiatr Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/acps.13594","article-title":"Weight and metabolic changes in early psychosis-association with daily\n                    quantification of medication exposure during the first hospitalization","volume":"148","author":"K Vochoskova","year":"2023","journal-title":"Acta Psychiatr Scand"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2007.02.024","article-title":"Weight gain in newly diagnosed first-episode psychosis patients and healthy\n                    comparisons: one-year analysis","volume":"93","author":"M Strassnig","year":"2007","journal-title":"Schizophr Res"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jamapsychiatry.2021.0015","article-title":"Association Between Cardiovascular Risk Factors and Cognitive Impairment in\n                    People With Schizophrenia: A Systematic Review and Meta-analysis","volume":"78","author":"K Hagi","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref47","first-page":"61","article-title":"Genetics of Common Antipsychotic-Induced Adverse Effects","volume":"2","author":"R R MacNeil","year":"2016","journal-title":"Mol Neuropsychiatry"},{"key":"ref48","first-page":"899","article-title":"Genetic association of the rs17782313 polymorphism with antipsychotic-induced\n                    weight gain","volume":"240","author":"K F Schreyer","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.numecd.2007.06.004","article-title":"Neuroendocrine control of food intake","volume":"18","author":"E Valassi","year":"2008","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40263-013-0062-1","article-title":"The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight\n                    gain","volume":"27","author":"M He","year":"2013","journal-title":"CNS Drugs"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1177\/0269881117722987","article-title":"Mechanisms underlying metabolic disturbances associated with psychosis and\n                    antipsychotic drug treatment","volume":"31","author":"G P Reynolds","year":"2017","journal-title":"J Psychopharmacol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/diabetes.54.5.1552","article-title":"Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion\n                    from perifused rat islets: role of muscarinic antagonism in\n                    antipsychotic-induced diabetes and hyperglycemia","volume":"54","author":"D E Johnson","year":"2005","journal-title":"Diabetes"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","article-title":"Research on adverse drug events. I. Muscarinic M3 receptor binding affinity\n                    could predict the risk of antipsychotics to induce type 2 diabetes","volume":"27","author":"J S Silvestre","year":"2005","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10401230701653377","article-title":"Should Depressive Syndromes Be Reclassified as \u201cMetabolic Syndrome Type\n                    II\u201d?","volume":"19","author":"R S McIntyre","year":"2007","journal-title":"Ann Clin Psychiatry"},{"key":"ref55","first-page":"18","article-title":"Reduced insulin sensitivity is related to less endogenous dopamine at D2\/3\n                    receptors in the ventral striatum of healthy nonobese humans","author":"F Caravaggio","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1530\/EC-16-0051","article-title":"Bromocriptine and insulin sensitivity in lean and obese subjects","volume":"5","author":"L Bahler","year":"2016","journal-title":"Endocr Connect"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0091-3057(87)90340-6","article-title":"Long term administration of some antipsychotic drugs increases body weight and\n                    feeding in rats. Are D2 dopamine receptors involved?","volume":"27","author":"T Baptista","year":"1987","journal-title":"Pharmacol Biochem Behav"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.schres.2016.04.051","article-title":"Adiposity-independent hypoadiponectinemia as a potential marker of insulin\n                    resistance and inflammation in schizophrenia patients treated with second\n                    generation antipsychotics","volume":"174","author":"M Sapra","year":"2016","journal-title":"Schizophr Res"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ijnp\/pyy075","article-title":"Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with\n                    Schizophrenia Taking Antipsychotics","volume":"22","author":"P Y Chen","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tem.2006.02.005","article-title":"Focus on prolactin as a metabolic hormone","volume":"17","author":"N Ben-Jonathan","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.2337\/dc12-1893","article-title":"Circulating prolactin associates with diabetes and impaired glucose regulation:\n                    a population-based study","volume":"36","author":"T Wang","year":"2013","journal-title":"Diabetes Care"},{"key":"ref62","first-page":"15","article-title":"Hyperleptinemia contributes to antipsychotic drug-associated obesity and\n                    metabolic disorders","author":"S Zhao","year":"2023","journal-title":"Sci Transl Med"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11920-014-0473-9","article-title":"Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers\n                    reviewed","volume":"16","author":"T A Shams","year":"2014","journal-title":"Curr Psychiatry Rep"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/070674370104600402","article-title":"Lithium revisited","volume":"46","author":"R S McIntyre","year":"2001","journal-title":"Can J Psychiatry"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41398-022-02122-6","article-title":"Insulin signaling as a therapeutic mechanism of lithium in bipolar disorder","volume":"12","author":"I H Campbell","year":"2022","journal-title":"Transl Psychiatry"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/met.2021.0078","article-title":"Gender and Body Mass Index-Related Serum Level of Adipokines and Metabolic\n                    Syndrome Components in Bipolar Patients Who Received Lithium and Valproic\n                    Acid","volume":"20","author":"M Marjani","year":"2022","journal-title":"Metab Syndr Relat Disord"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ps.20220584","article-title":"Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking\n                    Second-Generation Antipsychotics","volume":"75","author":"S Sanyal","year":"2024","journal-title":"Psychiatr Serv"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and\n                    diabetes","volume":"65","author":"American Diabetes A, American Psychiatric A, American\n                            Association of Clinical E, North American Association for the Study of\n                            O","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00406-023-01712-9","article-title":"Shared Decision Making Assistant (SDMA) and other digital tools for choosing\n                    antipsychotics in schizophrenia treatment","volume":"273","author":"S Leucht","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S2215-0366(23)00262-6","article-title":"Antidepressant and antipsychotic side-effects and personalised prescribing: a\n                    systematic review and digital tool development","volume":"10","author":"T Pillinger","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness\n                    position statement from the European Psychiatric Association (EPA), supported by\n                    the European Association for the Study of Diabetes (EASD) and the European\n                    Society of Cardiology (ESC)","volume":"24","author":"M De Hert","year":"2009","journal-title":"Eur Psychiatry"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1192\/bjo.2022.619","article-title":"Association between antipsychotic medication and clinically relevant weight\n                    change: meta-analysis","volume":"9","author":"B Campforts","year":"2023","journal-title":"BJPsych Open"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.clinthera.2005.12.005","article-title":"Effects of switching from olanzapine to risperidone on the prevalence of the\n                    metabolic syndrome in overweight or obese patients with schizophrenia or\n                    schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label\n                    study","volume":"27","author":"J M Meyer","year":"2005","journal-title":"Clin Ther"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/schbul\/sbad009","article-title":"Is Clozapine-induced Weight Gain Dose-dependent? Results From a Prospective\n                    Cohort Study","volume":"49","author":"M Piras","year":"2023","journal-title":"Schizophr Bull"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/schbul\/sbac001","article-title":"Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized\n                    Controlled Trials","volume":"48","author":"H Wu","year":"2022","journal-title":"Schizophr Bull"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"577919","DOI":"10.3389\/fendo.2021.577919","article-title":"Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and\n                    Meta-Analysis","volume":"12","author":"H Speyer","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","article-title":"Pharmacological strategies to counteract antipsychotic-induced weight gain and\n                    metabolic adverse effects in schizophrenia: a systematic review and\n                    meta-analysis","volume":"40","author":"Y Mizuno","year":"2014","journal-title":"Schizophr Bull"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/wps.20614","article-title":"The impact of pharmacological and non-pharmacological interventions to improve\n                    physical health outcomes in people with schizophrenia: a meta-review of\n                    meta-analyses of randomized controlled trials","volume":"18","author":"D Vancampfort","year":"2019","journal-title":"World Psychiatry"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/15622975.2011.592546","article-title":"Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced\n                    disturbances in body weight, blood glucose and lipid metabolism? Twenty-four-\n                    and 48-week results from a 6-month randomized trial","volume":"15","author":"J Cordes","year":"2014","journal-title":"World J Biol Psychiatry"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/jan.12012","article-title":"A randomized controlled trial undertaken to test a nurse-led weight management\n                    and exercise intervention designed for people with serious mental illness who\n                    take second generation antipsychotics","volume":"69","author":"K Usher","year":"2013","journal-title":"J Adv Nurs"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1214530","article-title":"A behavioral weight-loss intervention in persons with serious mental\n                    illness","volume":"368","author":"G L Daumit","year":"2013","journal-title":"N Engl J Med"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.4088\/JCP.14m09552","article-title":"Behavioral interventions for antipsychotic medication-associated obesity: a\n                    randomized, controlled clinical trial","volume":"77","author":"Z D Erickson","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.schres.2014.09.018","article-title":"Treatment response to the RENEW weight loss intervention in schizophrenia:\n                    impact of intervention setting","volume":"159","author":"C Brown","year":"2014","journal-title":"Schizophr Res"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"D B Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1176\/appi.ajp.2013.12010127","article-title":"Metformin for weight loss and metabolic control in overweight outpatients with\n                    schizophrenia and schizoaffective disorder","volume":"170","author":"L F Jarskog","year":"2013","journal-title":"Am J Psychiatry"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3389\/fphar.2018.01393","article-title":"Topiramate and Metformin Are Effective Add-On Treatments in Controlling\n                    Antipsychotic-Induced Weight Gain: A Systematic Review and Network\n                    Meta-Analysis","volume":"9","author":"C Zhuo","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13651501.2018.1449864","article-title":"Topiramate mitigates weight gain in antipsychotic-treated patients with\n                    schizophrenia: meta-analysis of randomised controlled trials","volume":"23","author":"K K Goh","year":"2019","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: a critical review of the evidence","volume":"3","author":"A Mehta","year":"2017","journal-title":"Obes Sci Pract"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in\n                    Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder:\n                    A Randomized Clinical Trial","volume":"74","author":"J R Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults\n                    with schizophrenia: A randomized controlled trial (CODEX)","volume":"20","author":"D J Siskind","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"ref92","first-page":"13","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in\n                    patients not responding to metformin \u2013 a case series","author":"F Prasad","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity. Reply","volume":"387","author":"A M Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jad.2021.04.017","article-title":"Psychiatric Safety and Weight Loss Efficacy of Naltrexone\/bupropion as Add-on to\n                    Antidepressant Therapy in Patients with Obesity or Overweight","volume":"289","author":"R S McIntyre","year":"2021","journal-title":"J Affect Disord"},{"key":"ref95","first-page":"84","article-title":"Olanzapine\/Samidorphan in Young Adults With Schizophrenia, Schizophreniform\n                    Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the\n                    Randomized, Controlled ENLIGHTEN-Early Study","author":"R S Kahn","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","article-title":"Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia:\n                    A 24-Week Phase 3 Study","volume":"177","author":"C U Correll","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/01.jcp.0000227354.54074.5d","article-title":"Bupropion treatment of olanzapine-associated weight gain: an open-label,\n                    prospective trial","volume":"26","author":"K M Gadde","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bdi.12109","article-title":"The effect of bariatric surgery on psychiatric course among patients with\n                    bipolar disorder","volume":"15","author":"A T Ahmed","year":"2013","journal-title":"Bipolar Disord"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jad.2018.12.113","article-title":"The long-term effect of bariatric surgery on depression and anxiety","volume":"246","author":"H Gill","year":"2019","journal-title":"J Affect Disord"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2405-5087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T23:33:11Z","timestamp":1741822391000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2405-5087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":97,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2405-5087","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]}}}